Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes
- PMID: 33619972
- PMCID: PMC8174263
- DOI: 10.1161/JAHA.120.019519
Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes
Abstract
The Go Red for Women movement was initiated by the American Heart Association (AHA) in the early 2000s to raise awareness concerning cardiovascular disease (CVD) risk in women. In 2016, the AHA funded 5 research centers across the United States to advance our knowledge of the risks and presentation of CVD that are specific to women. This report highlights the findings of the centers, showing how insufficient sleep, sedentariness, and pregnancy-related complications may increase CVD risk in women, as well as presentation and factors associated with myocardial infarction with nonobstructive coronary arteries and heart failure with preserved ejection fraction in women. These projects were augmented by collaborative ancillary studies assessing the relationships between various lifestyle behaviors, including nightly fasting duration, mindfulness, and behavioral and anthropometric risk factors and CVD risk, as well as metabolomic profiling of heart failure with preserved ejection fraction in women. The Go Red for Women Strategically Focused Research Network enhanced the evidence base related to heart disease in women, promoting awareness of the female-specific factors that influence CVD.
Keywords: health outcomes; heart failure; myocardial infarction; pregnancy; sedentary behavior; sleep; stress.
Conflict of interest statement
Dr Kass is coinventor on a submitted patent on the use of PDE9A inhibitors to treat obesity and related cardiometabolic disorders (Patent Cooperation Treaty submitted, patent pending). Dr Reynolds reports in‐kind support from Abbott Vascular and Siemens related to this publication and in‐kind support from BioTelemetry for an unrelated project. Dr Shah reports receiving grant funding from the, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, Amgen, Aria CV, AstraZeneca, Axon Therapies, Bayer, Boehringer‐Ingelheim, Boston Scientific, Bristol Myers Squibb, Coridea, Cyclerion, Cytokinetics, Edwards, Eisai, Imara, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Shifamed, and United Therapeutics. The remaining authors have no disclosures to report.
Figures
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
